JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Inicio・Lista de Acciones・Gossamer Bio Inc

Gossamer Bio Inc

Cerrado

SectorSanidad

2.26 -7

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2.22

Máximo

2.35

Métricas clave
By Trading Economics
Ingresos	-9.9M -48M
Ventas	1.8M 13M
Margen de beneficios	-362.728
Empleados	144
EBITDA	-10M -45M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+371.31% upside

Dividendos
By Dow Jones
Próximas Ganancias	11 mar 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	27M 574M
Apertura anterior	9.26
Cierre anterior	2.26

Noticias sobre sentimiento de mercado

By Acuity

100%

335 / 352 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

1.06 / 1.23 Soporte y Resistencia

Gossamer Bio Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

6 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

6 feb 2026, 21:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

6 feb 2026, 21:40 UTC

Adquisiciones, fusiones, absorciones

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6 feb 2026, 21:22 UTC

Charlas de Mercado

Mexico's Inflation Seen Accelerating in January -- Market Talk

6 feb 2026, 21:17 UTC

Ganancias

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6 feb 2026, 21:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

6 feb 2026, 21:14 UTC

Adquisiciones, fusiones, absorciones

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6 feb 2026, 21:13 UTC

Ganancias

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6 feb 2026, 21:13 UTC

Ganancias

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6 feb 2026, 21:04 UTC

Charlas de Mercado

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6 feb 2026, 20:34 UTC

Ganancias

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

6 feb 2026, 20:27 UTC

Ganancias

These Stocks Are Today's Movers: Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More -- Barrons.com

6 feb 2026, 20:24 UTC

Charlas de Mercado

Oil Futures Settle Higher As U.S.-Iran Talks Get Under Way -- Market Talk

6 feb 2026, 20:20 UTC

Charlas de Mercado

U.S. Natural Gas Futures Retreat Ahead of Weekend -- Market Talk

6 feb 2026, 19:48 UTC

Ganancias

Take-Two, Mondelez Get Analyst Attention -- Barrons.com

6 feb 2026, 19:30 UTC

Adquisiciones, fusiones, absorciones

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- WSJ

6 feb 2026, 19:30 UTC

Adquisiciones, fusiones, absorciones

Justice Department Asking Industry How Netflix or Paramount Deal for Warner Bros. Might Impact Competition, According to Subpoena -- WSJ

6 feb 2026, 19:30 UTC

Adquisiciones, fusiones, absorciones

DOJ Asking if Netflix Engaged in 'Exclusionary Conduct' That May Lead to Monopoly, According to Subpoena -- WSJ

6 feb 2026, 19:17 UTC

Charlas de Mercado

USDA Says Farm Income to Decrease in 2026 -- Market Talk

6 feb 2026, 18:50 UTC

Ganancias

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6 feb 2026, 18:47 UTC

Charlas de Mercado

Natural Gas-Infrastructure Operators Take 'Flight to Scale' -- Market Talk

6 feb 2026, 18:34 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By 1 to 412 -- Market Talk

6 feb 2026, 17:58 UTC

Ganancias

Reddit Stock Falls After Strong Earnings. Wall Street Is Debating What's Next. -- Barrons.com

6 feb 2026, 17:52 UTC

Charlas de Mercado

Ganancias

Global Equities Roundup: Market Talk

6 feb 2026, 17:52 UTC

Charlas de Mercado

Ganancias

Amazon's CapEx Seen as Misunderstood by Investors -- Market Talk

6 feb 2026, 17:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

6 feb 2026, 17:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

6 feb 2026, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

6 feb 2026, 17:18 UTC

Charlas de Mercado

Canada's Bizarre Jobs Report Points to Growing Labor Slack -- Market Talk

6 feb 2026, 17:09 UTC

Charlas de Mercado

Dollar on Path to Snap Weekly Losing Streak -- Market Talk

Comparación entre iguales

Cambio de precio

Gossamer Bio Inc previsión

Precio Objetivo

By TipRanks

371.31% repunte

Estimación a 12 Meses

Media 11.5 USD 371.31%

Máximo 15 USD

Mínimo 9 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Gossamer Bio Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Gossamer Bio Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.06 / 1.23Soporte y Resistencia

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentimiento

By Acuity

335 / 352 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.